LCM
KYMR icon

Legato Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Legato Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$405K Sell
4,862
-4,672
-49% -$370K 0.04% 573
2025
Q4 		$742K Buy
9,534
+2,751
+41% +$186K 0.06% 438
2025
Q3 		$384K Buy
+6,783
New +$306K 0.04% 475

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Legato Capital Management's KYMR Position: Q1 2026 in Review

Legato Capital Management reduced its Kymera Therapeutics (KYMR) stake by 49% in Q1 2026, selling an estimated $370K and leaving 4,862 shares worth $405K. The position accounts for 0.04% of the portfolio, ranked #573.

Legato Capital Management first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. The position peaked at $742K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Legato Capital Management held 4,862 shares of Kymera Therapeutics worth $405K as of Q1 2026.
  • Legato Capital Management sold 4,672 Kymera Therapeutics shares in Q1 2026, an estimated $370K.
  • Kymera Therapeutics made up 0.04% of Legato Capital Management's portfolio in Q1 2026, its #573 holding.
  • Legato Capital Management first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Legato Capital Management's Kymera Therapeutics position peaked at $742K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.